RAFAEL HOLDINGS, INC. Federal Income Tax Expense (Benefit), Continuing Operations
RAFAEL HOLDINGS, INC. (RFL) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$6.06 million for the 12-month period ending 2023-07-31, per its 10-K filed 2023-10-30.
Discontinued › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2023-10-30
- RAFAEL HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2023 was -$6.06M.
- RAFAEL HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2022 was -$137.98M.
- RAFAEL HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2021 was -$22.55M.
- RAFAEL HOLDINGS, INC. federal income tax expense (benefit), continuing operations for fiscal 2020 was -$6.21M.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month | Federal Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2023-07-31 | -$6.06M 10-K · filed 2023-10-30 | |
| 2022-07-31 | -$137.98M 10-K · filed 2023-10-30 | |
| 2021-07-31 | -$22.55M 10-K · filed 2022-10-31 | -$24.25M 10-K · filed 2021-10-18 |
| 2020-07-31 | -$6.21M 10-K · filed 2021-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |